Identification
NameSeocalcitol
Accession NumberDB04258  (EXPT01322)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
Synonyms
(5Z,7E,22E,24E)-(1S,3R)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
22-24-DIENE-24A,26A,27A,TRIHOMO-1ALPHA,25-DIHYDROXYVITAMIN D3
External IDs CB-1089 / EB-1089
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIQ0OZ0D9223
CAS number134404-52-7
WeightAverage: 454.6844
Monoisotopic: 454.344695338
Chemical FormulaC30H46O3
InChI KeyLVLLALCJVJNGQQ-SEODYNFXSA-N
InChI
InChI=1S/C30H46O3/c1-6-30(33,7-2)18-9-8-11-21(3)26-15-16-27-23(12-10-17-29(26,27)5)13-14-24-19-25(31)20-28(32)22(24)4/h8-9,11,13-14,18,21,25-28,31-33H,4,6-7,10,12,15-17,19-20H2,1-3,5H3/b11-8+,18-9+,23-13+,24-14-/t21-,25-,26-,27+,28+,29-/m1/s1
IUPAC Name
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5E)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
SMILES
[H]\C(\C(\[H])=C(/[H])C(O)(CC)CC)=C(\[H])[C@@]([H])(C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C(/[H])\C(\[H])=C1\C[C@@]([H])(O)C[C@]([H])(O)C1=C
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Vitamin D3 receptorProteinunknownNot AvailableHumanP11473 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Seocalcitol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Seocalcitol.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seocalcitol.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Seocalcitol.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Seocalcitol.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Seocalcitol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Seocalcitol.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Seocalcitol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seocalcitol.Approved, Investigational
FingolimodSeocalcitol may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Seocalcitol is combined with G17DT.Investigational
INGN 201The risk or severity of adverse effects can be increased when Seocalcitol is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Seocalcitol is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Natalizumab.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Seocalcitol.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Seocalcitol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seocalcitol.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Seocalcitol.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Seocalcitol is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Seocalcitol.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Seocalcitol.Approved
SRP 299The risk or severity of adverse effects can be increased when Seocalcitol is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Seocalcitol.Approved, Investigational
TofacitinibSeocalcitol may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Seocalcitol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedEducational/Counseling/TrainingNeoplasms, Hepatic1
Not AvailableTerminatedEducational/Counseling/TrainingNeoplasms, Hepatic1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00382 mg/mLALOGPS
logP6.59ALOGPS
logP5.27ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)14.39ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity142.26 m3·mol-1ChemAxon
Polarizability56.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.9064
Caco-2 permeable+0.7586
P-glycoprotein substrateSubstrate0.782
P-glycoprotein inhibitor INon-inhibitor0.6259
P-glycoprotein inhibitor IINon-inhibitor0.6716
Renal organic cation transporterNon-inhibitor0.8359
CYP450 2C9 substrateNon-substrate0.8427
CYP450 2D6 substrateNon-substrate0.8969
CYP450 3A4 substrateSubstrate0.7277
CYP450 1A2 substrateNon-inhibitor0.8674
CYP450 2C9 inhibitorNon-inhibitor0.8597
CYP450 2D6 inhibitorNon-inhibitor0.9287
CYP450 2C19 inhibitorNon-inhibitor0.8098
CYP450 3A4 inhibitorNon-inhibitor0.657
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5196
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.8961
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity4.2195 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8284
hERG inhibition (predictor II)Non-inhibitor0.7689
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassVitamin D and derivatives
Direct ParentVitamin D and derivatives
Alternative ParentsTriterpenoids / Tertiary alcohols / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
SubstituentsTriterpenoid / Tertiary alcohol / Cyclic alcohol / Secondary alcohol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Alcohol / Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsVitamin D3 and derivatives (LMST03020449 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B/WSTF which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.
Gene Name:
VDR
Uniprot ID:
P11473
Molecular Weight:
48288.64 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 20:54